CD4 and melanoma: Follow‐up investigations demonstrated that the S. typhimurium‐NY‐ESO‐1 vaccine prompted the development of CD4+ T helper 1 (Th1) cells in melanoma patients without inherent NY‐ESO‐1 immunity.